Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning

Lauren B. Gerlach, Helen C. Kales, Donovan T. Maust, Claire Chiang, Claire Stano, Hae Mi Choe, Kara Zivin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives In 2011, the U.S. Food and Drug Administration (FDA) issued a safety announcement cautioning providers against prescribing citalopram above 40 mg per day given concerns for QT prolongation. We assessed the impact of a health system quality improvement initiative to identify patients taking higher than the recommended dose of citalopram. Design Retrospective cohort study. Setting Nine primary care clinics within the University of Michigan from March 2012 to February 2013. Participants Adult patients taking a higher-than-recommended dose of citalopram following the FDA warning in 2011 (N = 199). Measurements Frequency of EKG monitoring, clinical factors associated with patients whose citalopram dose or use was adjusted, and potential impact of these changes on overall health care utilization was assessed. Results In patients prescribed higher-than-recommended doses of citalopram and who received a note from a pharmacist regarding the FDA warnings, only 8.5% received electrocardiogram (EKG) monitoring. Patients who were converted to an alternative antidepressant from citalopram were more likely to receive subsequent new prescriptions for benzodiazepines and sedative hypnotics (χ2 = 7.9, p = 0.048). Patients who had any adjustments to their antidepressant medication had greater overall health care utilization (OR: 25.0; 95% CI: 5.7–109.6; p < 0.001) than patients remaining on the same dose of citalopram. Conclusions Despite a targeted quality intervention to address the FDA warning regarding citalopram, the warning was associated with low levels of EKG monitoring, increased anxiolytic and sedative medication use, and higher healthcare utilization. This finding may represent destabilization of patients on previously therapeutic doses of their antidepressant and an unintended consequence of the FDA warning.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalAmerican Journal of Geriatric Psychiatry
Volume25
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Citalopram
United States Food and Drug Administration
Prescriptions
Electrocardiography
Patient Acceptance of Health Care
Antidepressive Agents
Hypnotics and Sedatives
Anti-Anxiety Agents
Quality Improvement
Benzodiazepines
Pharmacists
Primary Health Care
Cohort Studies
Retrospective Studies
Delivery of Health Care
Safety
Health

Keywords

  • Citalopram
  • EKG monitoring
  • FDA warning
  • QT prolongation

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning. / Gerlach, Lauren B.; Kales, Helen C.; Maust, Donovan T.; Chiang, Claire; Stano, Claire; Choe, Hae Mi; Zivin, Kara.

In: American Journal of Geriatric Psychiatry, Vol. 25, No. 4, 01.04.2017, p. 407-414.

Research output: Contribution to journalArticle

Gerlach, Lauren B. ; Kales, Helen C. ; Maust, Donovan T. ; Chiang, Claire ; Stano, Claire ; Choe, Hae Mi ; Zivin, Kara. / Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning. In: American Journal of Geriatric Psychiatry. 2017 ; Vol. 25, No. 4. pp. 407-414.
@article{98249a5a4079457da25f2a3026d1c014,
title = "Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning",
abstract = "Objectives In 2011, the U.S. Food and Drug Administration (FDA) issued a safety announcement cautioning providers against prescribing citalopram above 40 mg per day given concerns for QT prolongation. We assessed the impact of a health system quality improvement initiative to identify patients taking higher than the recommended dose of citalopram. Design Retrospective cohort study. Setting Nine primary care clinics within the University of Michigan from March 2012 to February 2013. Participants Adult patients taking a higher-than-recommended dose of citalopram following the FDA warning in 2011 (N = 199). Measurements Frequency of EKG monitoring, clinical factors associated with patients whose citalopram dose or use was adjusted, and potential impact of these changes on overall health care utilization was assessed. Results In patients prescribed higher-than-recommended doses of citalopram and who received a note from a pharmacist regarding the FDA warnings, only 8.5{\%} received electrocardiogram (EKG) monitoring. Patients who were converted to an alternative antidepressant from citalopram were more likely to receive subsequent new prescriptions for benzodiazepines and sedative hypnotics (χ2 = 7.9, p = 0.048). Patients who had any adjustments to their antidepressant medication had greater overall health care utilization (OR: 25.0; 95{\%} CI: 5.7–109.6; p < 0.001) than patients remaining on the same dose of citalopram. Conclusions Despite a targeted quality intervention to address the FDA warning regarding citalopram, the warning was associated with low levels of EKG monitoring, increased anxiolytic and sedative medication use, and higher healthcare utilization. This finding may represent destabilization of patients on previously therapeutic doses of their antidepressant and an unintended consequence of the FDA warning.",
keywords = "Citalopram, EKG monitoring, FDA warning, QT prolongation",
author = "Gerlach, {Lauren B.} and Kales, {Helen C.} and Maust, {Donovan T.} and Claire Chiang and Claire Stano and Choe, {Hae Mi} and Kara Zivin",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jagp.2016.11.010",
language = "English (US)",
volume = "25",
pages = "407--414",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning

AU - Gerlach, Lauren B.

AU - Kales, Helen C.

AU - Maust, Donovan T.

AU - Chiang, Claire

AU - Stano, Claire

AU - Choe, Hae Mi

AU - Zivin, Kara

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objectives In 2011, the U.S. Food and Drug Administration (FDA) issued a safety announcement cautioning providers against prescribing citalopram above 40 mg per day given concerns for QT prolongation. We assessed the impact of a health system quality improvement initiative to identify patients taking higher than the recommended dose of citalopram. Design Retrospective cohort study. Setting Nine primary care clinics within the University of Michigan from March 2012 to February 2013. Participants Adult patients taking a higher-than-recommended dose of citalopram following the FDA warning in 2011 (N = 199). Measurements Frequency of EKG monitoring, clinical factors associated with patients whose citalopram dose or use was adjusted, and potential impact of these changes on overall health care utilization was assessed. Results In patients prescribed higher-than-recommended doses of citalopram and who received a note from a pharmacist regarding the FDA warnings, only 8.5% received electrocardiogram (EKG) monitoring. Patients who were converted to an alternative antidepressant from citalopram were more likely to receive subsequent new prescriptions for benzodiazepines and sedative hypnotics (χ2 = 7.9, p = 0.048). Patients who had any adjustments to their antidepressant medication had greater overall health care utilization (OR: 25.0; 95% CI: 5.7–109.6; p < 0.001) than patients remaining on the same dose of citalopram. Conclusions Despite a targeted quality intervention to address the FDA warning regarding citalopram, the warning was associated with low levels of EKG monitoring, increased anxiolytic and sedative medication use, and higher healthcare utilization. This finding may represent destabilization of patients on previously therapeutic doses of their antidepressant and an unintended consequence of the FDA warning.

AB - Objectives In 2011, the U.S. Food and Drug Administration (FDA) issued a safety announcement cautioning providers against prescribing citalopram above 40 mg per day given concerns for QT prolongation. We assessed the impact of a health system quality improvement initiative to identify patients taking higher than the recommended dose of citalopram. Design Retrospective cohort study. Setting Nine primary care clinics within the University of Michigan from March 2012 to February 2013. Participants Adult patients taking a higher-than-recommended dose of citalopram following the FDA warning in 2011 (N = 199). Measurements Frequency of EKG monitoring, clinical factors associated with patients whose citalopram dose or use was adjusted, and potential impact of these changes on overall health care utilization was assessed. Results In patients prescribed higher-than-recommended doses of citalopram and who received a note from a pharmacist regarding the FDA warnings, only 8.5% received electrocardiogram (EKG) monitoring. Patients who were converted to an alternative antidepressant from citalopram were more likely to receive subsequent new prescriptions for benzodiazepines and sedative hypnotics (χ2 = 7.9, p = 0.048). Patients who had any adjustments to their antidepressant medication had greater overall health care utilization (OR: 25.0; 95% CI: 5.7–109.6; p < 0.001) than patients remaining on the same dose of citalopram. Conclusions Despite a targeted quality intervention to address the FDA warning regarding citalopram, the warning was associated with low levels of EKG monitoring, increased anxiolytic and sedative medication use, and higher healthcare utilization. This finding may represent destabilization of patients on previously therapeutic doses of their antidepressant and an unintended consequence of the FDA warning.

KW - Citalopram

KW - EKG monitoring

KW - FDA warning

KW - QT prolongation

UR - http://www.scopus.com/inward/record.url?scp=85010738780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010738780&partnerID=8YFLogxK

U2 - 10.1016/j.jagp.2016.11.010

DO - 10.1016/j.jagp.2016.11.010

M3 - Article

C2 - 28012712

AN - SCOPUS:85010738780

VL - 25

SP - 407

EP - 414

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 4

ER -